Macrophage recognition of toxic advanced glycosylation end products through the macrophage surface-receptor nucleolin

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 4, 2014, Pages 588-596

  Miki, Yuichi ^a   Dambara, Hikaru ^a   Tachibana, Yoshihiro ^a   Hirano, Kazuya ^a   Konishi, Mio ^a   Beppu, Masatoshi ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Advanced glycosylation end product (AGE); Glyceraldehyde; Glycolaldehyde; Macrophage; Nucleolin; Toxic AGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ARGININE; BOVINE SERUM ALBUMIN; GLYCERALDEHYDE; NUCLEOLIN; ACETALDEHYDE; AGRO 100; GLYCOLALDEHYDE; IMMUNOGLOBULIN G; OLIGODEOXYRIBONUCLEOTIDE; PHOSPHOPROTEIN; RNA BINDING PROTEIN;

ADULT; ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; MALE; MOLECULAR SIZE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BOVINE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; MACROPHAGE; METABOLISM;

ACETALDEHYDE; ANIMALS; CATTLE; GLYCERALDEHYDE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN G; MACROPHAGES; MALE; MICE; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHOPROTEINS; RNA-BINDING PROTEINS; SERUM ALBUMIN, BOVINE; TRANSFECTION;

EID: 84898736849     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00818     Document Type: Article

References (49)

1. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann. Intern. Med., 101, 527-537 (1984).
2. Takata K, Horiuchi S, Araki N, Shiga M, Saitoh M, Morino Y. Scavenger receptor of human monocytic leukemia cell line (THP-1) and murine macrophages for nonenzymatically glycosylated proteins. Biochim. Biophys. Acta, 986, 18-26 (1989).
3. Takata K, Horiuchi S, Araki N, Shiga M, Saitoh M, Morino Y. Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. J. Biol. Chem., 263, 14819-14825 (1988).
4. Takeuchi M, Yanase Y, Matsuura N, Yamagishi Si S, Kameda Y, Bucala R, Makita Z. Immunological detection of a novel advanced glycation end-product. Mol. Med., 7, 783-791 (2001).
5. Hamada Y, Araki N, Koh N, Nakamura J, Horiuchi S, Hotta N. Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem. Biophys. Res. Commun., 228, 539-543 (1996).
6. Takeuchi M, Yamagishi S. TAGE (toxic AGEs) hypothesis in various chronic diseases. Med. Hypotheses, 63, 449-452 (2004).
7. Takeuchi M, Takino J, Yamagishi S. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy. Curr. Drug Targets, 11, 1468-1482 (2010).
8. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest., 108, 949-955 (2001).
9. Pugliese G, Pricci F, Iacobini C, Leto G, Amadio L, Barsotti P, Frigeri L, Hsu DK, Vlassara H, Liu FT, Di Mario U. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J., 15, 2471-2479 (2001).
10. Araki N, Higashi T, Mori T, Shibayama R, Kawabe Y, Kodama T, Takahashi K, Shichiri M, Horiuchi S. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur. J. Biochem., 230, 408-415 (1995).
11. Horiuchi S, Sakamoto Y, Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids, 25, 283-292 (2003).
12. Nagai R, Matsumoto K, Ling X, Suzuki H, Araki T, Horiuchi S. Glycolaldehyde, a reactive intermediate for advanced glycation end products, plays an important role in the generation of an active ligand for the macrophage scavenger receptor. Diabetes, 49, 1714-1723 (2000).
13. Sano H, Nagai R, Matsumoto K, Horiuchi S. Receptors for proteins modified by advanced glycation endproducts (AGE) - their functional role in atherosclerosis. Mech. Ageing Dev., 107, 333-346 (1999).
14. Ohgami N, Nagai R, Ikemoto M, Arai H, Miyazaki A, Hakamata H, Horiuchi S, Nakayama H. CD36, serves as a receptor for advanced glycation endproducts (AGE). J. Diabetes Complications, 16, 56-59 (2002).
15. Ohgami N, Miyazaki A, Sakai M, Kuniyasu A, Nakayama H, Horiuchi S. Advanced glycation end products (AGE) inhibit scavenger receptor class B type I-mediated reverse cholesterol transport: a new crossroad of AGE to cholesterol metabolism. J. Atheroscler. Thromb., 10, 1-6 (2003).
16. Jono T, Miyazaki A, Nagai R, Sawamura T, Kitamura T, Horiuchi S. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett., 511, 170-174 (2002).
17. Nagai R, Fujiwara Y, Mera K, Otagiri M. Investigation of pathways of advanced glycation end-products accumulation in macrophages. Mol. Nutr. Food Res., 51, 462-467 (2007).
18. Nagai R, Hayashi CM, Xia L, Takeya M, Horiuchi S. Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehyde-modified proteins. J. Biol. Chem., 277, 48905-48912 (2002).
19. Ginisty H, Sicard H, Roger B, Bouvet P. Structure and functions of nucleolin. J. Cell Sci., 112, 761-772 (1999).
20. Nigg EA. Nucleocytoplasmic transport: signals, mechanisms and regulation. Nature, 386, 779-787 (1997).
21. Hirano K, Miki Y, Hirai Y, Sato R, Itoh T, Hayashi A, Yamanaka M, Eda S, Beppu M. A multifunctional shuttling protein nucleolin is a macrophage receptor for apoptotic cells. J. Biol. Chem., 280, 39284-39293 (2005).
22. Miki Y, Itoh T, Hirano K, Eda S, Hayashi A, Yamanaka M, Beppu M. Clearance of oxidatively damaged cells by macrophages: recognition of glycoprotein clusters by macrophage-surface nucleolin as early apoptotic cells. Biol. Pharm. Bull., 32, 564-572 (2009).
23. Oguri E, Miki Y, Hirano K, Yamanaka M, Beppu M. Clearance of CD43-capped cells by macrophages: capping alone leads to phagocytosis. Biol. Pharm. Bull., 35, 551-558 (2012).
24. Miki Y, Oguri E, Hirano K, Beppu M. Macrophage recognition of cells with elevated calcium is mediated by carbohydrate chains of CD43. Cell Struct. Funct., 38, 43-54 (2013).
25. Ozawa D, Nakamura T, Koike M, Hirano K, Miki Y, Beppu M. Shuttling protein nucleolin is a microglia receptor for amyloid beta peptide 1-42. Biol. Pharm. Bull., 36, 1587-1593 (2013).
26. Semenkovich CF, Ostlund RE Jr, Olson MO, Yang JW. A protein partially expressed on the surface of HepG2 cells that binds lipoproteins specifically is nucleolin. Biochemistry, 29, 9708-9713 (1990).
27. de Verdugo UR, Selinka HC, Huber M, Kramer B, Kellermann J, Hofschneider PH, Kandolf R. Characterization of a 100-kilodalton binding protein for the six serotypes of coxsackie B viruses. J. Virol., 69, 6751-6757 (1995).
28. Nisole S, Said EA, Mische C, Prevost MC, Krust B, Bouvet P, Bianco A, Briand JP, Hovanessian AG. The anti-HIV pentameric pseudopeptide HB-19 binds the C-terminal end of nucleolin and prevents anchorage of virus particles in the plasma membrane of target cells. J. Biol. Chem., 277, 20877-20886 (2002).
29. Bose S, Basu M, Banerjee AK. Role of nucleolin in human parainfluenza virus type 3 infection of human lung epithelial cells. J. Virol., 78, 8146-8158 (2004).
30. Sinclair JF, O'Brien AD. Cell surface-localized nucleolin is a eukaryotic receptor for the adhesin intimin-gamma of enterohemorrhagic Escherichia coli O157 : H7. J. Biol. Chem., 277, 2876-2885 (2002).
31. Jordan G. At the heart of the nucleolus. Nature, 329, 489-490 (1987).
32. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275 (1951).
33. Habeeb AF. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal. Biochem., 14, 328-336 (1966).
34. Sattarahmady N, Moosavi-Movahedi AA, Ahmad F, Hakimelahi GH, Habibi-Rezaei M, Saboury AA, Sheibani N. Formation of the molten globule-like state during prolonged glycation of human serum albumin. Biochim. Biophys. Acta, 1770, 933-942 (2007).
35. Miksa M, Komura H, Wu R, Shah KG, Wang P. A novel method to determine the engulfment of apoptotic cells by macrophages using pHrodo succinimidyl ester. J. Immunol. Methods, 342, 71-77 (2009).
36. Van Regenmortel MH. Use of biosensors to characterize recombinant proteins. Dev. Biol. Stand., 83, 143-151 (1994).
37. Mongelard F, Bouvet P. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr. Opin. Mol. Ther., 12, 107-114 (2010).
38. Miki Y, Tazawa T, Hirano K, Matsushima H, Kumamoto S, Hamasaki N, Yamaguchi T, Beppu M. Clearance of oxidized erythrocytes by macrophages: involvement of caspases in the generation of clearance signal at band 3 glycoprotein. Biochem. Biophys. Res. Commun., 363, 57-62 (2007).
39. Hampton RY, Golenbock DT, Penman M, Krieger M, Raetz CR. Recognition and plasma clearance of endotoxin by scavenger receptors. Nature, 352, 342-344 (1991).
40. Hou L, Shao H, Zhang Y, Li H, Menon NK, Neuhaus EB, Brewer JM, Byeon IJ, Ray DG, Vitek MP, Iwashita T, Makula RA, Przybyla AB, Zagorski MG. Solution NMR studies of the A beta(1-40) and A beta(1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J. Am. Chem. Soc., 126, 1992-2005 (2004).
41. Acharya AS, Manning JM. Reaction of glycolaldehyde with proteins: latent crosslinking potential of alpha-hydroxyaldehydes. Proc. Natl. Acad. Sci. U.S.A., 80, 3590-3594 (1983).
42. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med., 4, 1025-1031 (1998).
43. Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem. Pharmacol., 79, 1379-1386 (2010).
44. Liu J, Yin L, Dong H, Xu E, Zhang L, Qiao Y, Liu Y, Li L, Jia J. Decreased serum levels of nucleolin protein fragment, as analyzed by bead-based proteomic technology, in multiple sclerosis patients compared to controls. J. Neuroimmunol., 250, 71-76 (2012).
45. Ando K, Beppu M, Kikugawa K, Nagai R, Horiuchi S. Membrane proteins of human erythrocytes are modified by advanced glycation end products during aging in the circulation. Biochem. Biophys. Res. Commun., 258, 123-127 (1999).
46. Bryszewska M, Szosland K. Association between the glycation of erythrocyte membrane proteins and membrane fluidity. Clin. Biochem., 21, 49-51 (1988).
47. Watala C, Winocour PD. The relationship of chemical modification of membrane proteins and plasma lipoproteins to reduced membrane fluidity of erythrocytes from diabetic subjects. Eur. J. Clin. Chem. Clin. Biochem., 30, 513-519 (1992).
48. Vlassara H, Valinsky J, Brownlee M, Cerami C, Nishimoto S, Cerami A. Advanced glycosylation endproducts on erythrocyte cell surface induce receptor-mediated phagocytosis by macrophages. A model for turnover of aging cells. J. Exp. Med., 166, 539-549 (1987).
49. Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Zoukourian C, Capron L, Chappey O, Yan SD, Brett J, Guillausseau PJ, Stern D. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc. Natl. Acad. Sci. U.S.A., 91, 7742-7746 (1994).